

Supplemental table 1 Pairwise comparison of receiver operating characteristic curves predicting overall survival among the 598 HCC patients treated with palliative treatment.

Object	Factor 1	Factor 2	Difference	P value
Training cohort	AST	LYM	0.061	0.003
	AST	ALRI	0.063	0.025
	LYM	ALRI	0.124	<0.001
Validation cohort I	AST	LYM	0.014	0.781
	AST	ALRI	0.105	0.101
	LYM	ALRI	0.120	0.021

AST: aspartate aminotransferase; LYM: lymphocyte; ALRI: aspartate aminotransferase to lymphocyte ratio

Supplemental table 2: Pairwise comparison of receiver operating characteristic curves predicting overall survival.

Overall survival	System	System	Difference	P value
3-month	ALRI	ALRI-TNM	0.055	0.007
	ALRI	TNM	0.004	0.892
	ALRI	Nomogram	0.217	<0.001
	ALRI-TNM	TNM	0.059	<0.001
	ALRI-TNM	Nomogram	0.162	<0.001
	TNM	Nomogram	0.221	<0.001
6-month	ALRI	ALRI-TNM	0.078	<0.001
	ALRI	TNM	0.028	0.326
	ALRI	Nomogram	0.204	<0.001
	ALRI-TNM	TNM	0.051	<0.001
	ALRI-TNM	Nomogram	0.126	<0.001
	TNM	Nomogram	0.177	<0.001
1-year	ALRI	ALRI-TNM	0.078	<0.001
	ALRI	TNM	0.034	0.022
	ALRI	Nomogram	0.173	<0.001
	ALRI-TNM	TNM	0.044	<0.001
	ALRI-TNM	Nomogram	0.095	<0.001
	TNM	Nomogram	0.139	<0.001
2-year	ALRI	ALRI-TNM	0.043	0.031
	ALRI	TNM	0.007	0.802
	ALRI	Nomogram	0.168	<0.001
	ALRI-TNM	TNM	0.036	0.009
	ALRI-TNM	Nomogram	0.125	<0.001
	TNM	Nomogram	0.161	<0.001

ALRI: aspartate aminotransferase to lymphocyte ratio; TNM: tumor-node-metastasis.